e-learning
resources
Barcelona 2010
Monday, 20.09.2010
Pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Single centre experience of connective tissue disease (CTD) associated pulmonary arterial hypertension (PAH): Impact of a supra-regional screening programme
J. Hurdman, R. Condliffe, C. A. Elliot, R. Kilding, M. Akil, C. Billings, I. Armstrong, N. Hamilton, D. G. Kiely (Sheffield, United Kingdom)
Source:
Annual Congress 2010 - Pulmonary hypertension
Session:
Pulmonary hypertension
Session type:
E-Communication Session
Number:
3523
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Hurdman, R. Condliffe, C. A. Elliot, R. Kilding, M. Akil, C. Billings, I. Armstrong, N. Hamilton, D. G. Kiely (Sheffield, United Kingdom). Single centre experience of connective tissue disease (CTD) associated pulmonary arterial hypertension (PAH): Impact of a supra-regional screening programme. Eur Respir J 2010; 36: Suppl. 54, 3523
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Middle-long term pulmonary abnormalities after severe COVID-19 pneumonia which required invasive ventilation
Post partum
dyspnoea: look beyond the lungs
Related content which might interest you:
Characteristics of idiopathic pulmonary arterial hypertension (IPAH) and PAH associated with connective tissue disease (APAH-CTD) patients in PROSPECT
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013
Sitaxsentan improves 6MW and hemodynamics in patients with pulmonary arterial hypertension (PAH) related to connective tissue disease (CTD)
Source: Eur Respir J 2005; 26: Suppl. 49, 564s
Year: 2005
Pulmonary arterial hypertension associated with connective tissue disease: an integrated approach
Source: Annual Congress 2008 - Mastering pulmonary arterial hypertension: defined by evidence - enhanced by experience
Year: 2008
Oxygen pulse slope analysis during exercise testing identifies patients with systemic sclerosis at a possible risk for developing pulmonary vasculopathy
Source: Annual Congress 2013 –Clinical exercise physiology
Year: 2013
Early risk prediction in idiopathic
versus
connective tissue disease-associated pulmonary arterial hypertension: call for a refined assessment
Source: ERJ Open Res, 7 (3) 00854-2020; 10.1183/23120541.00854-2020
Year: 2021
ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre
Source: Eur Respir J 2012; 39: 945-955
Year: 2012
Initial experience of sildenafil in patients with congenital heart disease (CHD) associated pulmonary arterial hypertension (PAH)
Source: Eur Respir J 2006; 28: Suppl. 50, 425s
Year: 2006
PAH-specific therapies improve survival in patients with pulmonary arterial hypertension associated with connective tissue diseases: A Russian single centre experience
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Risk stratification of pulmonary arterial hypertension (PAH) associated with adult congenital heart disease (ACHD)
Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension
Year: 2019
An international survey of current pulmonary arterial hypertension (PAH) management
Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments
Year: 2012
An evaluation of outcomes for patients with pulmonary hypertension (PH) incorporated into a standard UK pulmonary rehabilitation (PR) programme
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016
Impact of pulmonary arterial hypertension (PAH) on the lives of patients and carers
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I
Year: 2013
Impact of initiation of sildenafil on patterns of healthcare utilization and cost in patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2010 - Pulmonary circulation: clinical aspects
Year: 2010
Usefulness of differential blood gas exchange assessment in patients with severe pulmonary arterial hypertension (PAH) associated to congenital heart disease (CHD)
Source: Eur Respir J 2005; 26: Suppl. 49, 351s
Year: 2005
Characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease in the French PAH registry
Source: Annual Congress 2011 - Clinical characteristics of patients with pulmonary hypertension
Year: 2011
Refining definitions of time to clinical worsening in connective tissue disease-associated pulmonary arterial hypertension
Source: Annual Congress 2010 - Pulmonary hypertension
Year: 2010
Clinical meaning of low DLCO in idiopathic pulmonary arterial hypertension (IPAH) - Prospective single centre study
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
Smoking history and pulmonary arterial hypertension (PAH) onset and clinical outcomes (REVEAL)
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management
Source: Eur Respir Rev 2010 19: 314-320
Year: 2010
Pulmonary arterial hypertension (PAH) in patients with lung sarcoidosis (LS)
Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept